CN104718004A - 新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物 - Google Patents

新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物 Download PDF

Info

Publication number
CN104718004A
CN104718004A CN201380055225.0A CN201380055225A CN104718004A CN 104718004 A CN104718004 A CN 104718004A CN 201380055225 A CN201380055225 A CN 201380055225A CN 104718004 A CN104718004 A CN 104718004A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
ring
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380055225.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.M.阿普加
A.阿拉萨潘
T.比夫图
陈萍
冯丹青
E.圭德里
J.希克斯
A.克克奇
K.利维特
厉冰
T.麦克拉肯
I.塞巴特
X.钱
魏兰
R.维尔克宁
吴志才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN104718004A publication Critical patent/CN104718004A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201380055225.0A 2012-08-22 2013-08-19 新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物 Pending CN104718004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692018P 2012-08-22 2012-08-22
US61/692018 2012-08-22
PCT/US2013/055528 WO2014031515A1 (en) 2012-08-22 2013-08-19 Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives

Publications (1)

Publication Number Publication Date
CN104718004A true CN104718004A (zh) 2015-06-17

Family

ID=50150322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055225.0A Pending CN104718004A (zh) 2012-08-22 2013-08-19 新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物

Country Status (12)

Country Link
US (1) US9290517B2 (https=)
EP (1) EP2888005B1 (https=)
JP (1) JP2015526468A (https=)
KR (1) KR20150045436A (https=)
CN (1) CN104718004A (https=)
AR (1) AR092201A1 (https=)
AU (1) AU2013306030A1 (https=)
BR (1) BR112015003109A2 (https=)
CA (1) CA2881836A1 (https=)
RU (1) RU2015109706A (https=)
TW (1) TW201412751A (https=)
WO (1) WO2014031515A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503927A (zh) * 2016-01-11 2016-04-20 沧州普瑞东方科技有限公司 一种合成3,6-二氢-2h-吡(噻)喃-4-硼酸酯的方法
CN106478653A (zh) * 2016-10-16 2017-03-08 云南民族大学 异山梨醇—单咪唑盐类化合物及其制备方法
CN111423435A (zh) * 2020-03-30 2020-07-17 厦门大学 (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
CN113891891A (zh) * 2019-03-05 2022-01-04 戒毒及精神健康中心 Ampa受体信号转导的调节剂
CN115944612A (zh) * 2022-12-23 2023-04-11 敖虎山 胰高血糖素拮抗剂阿度格列凡的新用途
CN116390925A (zh) * 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN117838690A (zh) * 2023-10-09 2024-04-09 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
WO2014031468A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031517A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
TR201806860T4 (tr) * 2013-07-17 2018-06-21 Boehringer Ingelheim Int Yeni azabenzimidazol türevleri.
US9980948B2 (en) 2014-08-27 2018-05-29 Shionogi & Co., Ltd. Azaindole derivative having AMPK-activating activity
MX2017005158A (es) 2014-10-28 2017-07-27 Shionogi & Co Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
JP6612880B2 (ja) * 2015-01-16 2019-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｍｐ活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体
EA201890086A1 (ru) * 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
JPWO2017146186A1 (ja) 2016-02-26 2018-12-20 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有する５−フェニルアザインドール誘導体
CN109476661A (zh) 2016-05-20 2019-03-15 盐野义制药株式会社 具有ampk活化作用的5-取代苯并咪唑及5-取代氮杂苯并咪唑衍生物
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
EP4320126A4 (en) * 2021-04-09 2026-03-18 Broad Inst Inc Bifunctional molecules for the selective modification of target substrates
AU2023313032A1 (en) * 2022-07-28 2025-01-23 Ac Immune Sa Novel compounds
KR102638391B1 (ko) * 2023-05-30 2024-02-20 삼화페인트공업주식회사 다이알칸설포닐 아이소소바이드 화합물의 제조 방법, 리튬이차전지용 전해액 첨가제, 리튬이차전지용 전해액 및 리튬이차전지

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106273A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102361857A (zh) * 2008-09-26 2012-02-22 默沙东公司 可用作抗糖尿病剂的新颖的环状苯并咪唑衍生物
TW201217372A (en) * 2010-09-10 2012-05-01 Shionogi & Amp Co Ltd Heterocycle fused imidazole derivative having AMPK activating activity
CN103476258A (zh) * 2011-02-25 2013-12-25 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58193541A (ja) 1982-05-07 1983-11-11 Konishiroku Photo Ind Co Ltd 熱現像画像記録材料
JPH0245181B2 (ja) 1983-03-16 1990-10-08 Fuji Photo Film Co Ltd Netsugenzokaraakankozairyo
GB8313322D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Heterocyclic-(cyclo)aliphatic carboxylic acids
GB8313321D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Preparation of mercaptan substituted carboxylic acids
GB8313320D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Coating compositions
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JPH06298731A (ja) 1993-04-13 1994-10-25 Fuji Photo Film Co Ltd 複素環化合物の製造方法
AU683287B2 (en) * 1993-07-23 1997-11-06 Merrell Pharmaceuticals Inc. Novel 9-N-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU758789B2 (en) 1998-07-15 2003-03-27 Teijin Limited Thiobenzimidazole derivatives
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
CN100415723C (zh) 2000-01-17 2008-09-03 帝人株式会社 苯并咪唑衍生物
WO2001053272A1 (en) 2000-01-17 2001-07-26 Teijin Limited Human chymase inhibitors
WO2002040019A1 (en) 2000-11-15 2002-05-23 Banyu Pharmaceutical Co.,Ltd. Benzimidazole derivatives
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
EP1419785A4 (en) 2001-08-24 2005-07-06 Teijin Ltd MEDICAMENTS CONTAINING A CHYMASE INHIBITOR AND ACE INHIBITOR AS ACTIVE INGREDIENTS
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
US20050148643A1 (en) 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme
US20070032466A1 (en) 2003-08-22 2007-02-08 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006094209A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-benzimidazolylalkyl-substituted amide sirtuin modulators
EP1884513A4 (en) 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
JP2009500351A (ja) 2005-07-04 2009-01-08 ドクター レディズ ラボラトリーズ リミテッド Ａｍｐｋアクチベータとしてのチアゾール誘導体
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010047982A1 (en) * 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2014031517A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
WO2014031468A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361857A (zh) * 2008-09-26 2012-02-22 默沙东公司 可用作抗糖尿病剂的新颖的环状苯并咪唑衍生物
WO2011106273A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TW201217372A (en) * 2010-09-10 2012-05-01 Shionogi & Amp Co Ltd Heterocycle fused imidazole derivative having AMPK activating activity
CN103476258A (zh) * 2011-02-25 2013-12-25 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503927A (zh) * 2016-01-11 2016-04-20 沧州普瑞东方科技有限公司 一种合成3,6-二氢-2h-吡(噻)喃-4-硼酸酯的方法
CN106478653A (zh) * 2016-10-16 2017-03-08 云南民族大学 异山梨醇—单咪唑盐类化合物及其制备方法
CN113891891A (zh) * 2019-03-05 2022-01-04 戒毒及精神健康中心 Ampa受体信号转导的调节剂
CN113891891B (zh) * 2019-03-05 2024-10-11 戒毒及精神健康中心 Ampa受体信号转导的调节剂
CN111423435A (zh) * 2020-03-30 2020-07-17 厦门大学 (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
CN111423435B (zh) * 2020-03-30 2021-10-15 厦门大学 (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
CN116390925A (zh) * 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN115944612A (zh) * 2022-12-23 2023-04-11 敖虎山 胰高血糖素拮抗剂阿度格列凡的新用途
CN117838690A (zh) * 2023-10-09 2024-04-09 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Also Published As

Publication number Publication date
KR20150045436A (ko) 2015-04-28
CA2881836A1 (en) 2014-02-27
JP2015526468A (ja) 2015-09-10
AU2013306030A1 (en) 2015-02-05
TW201412751A (zh) 2014-04-01
US20150284411A1 (en) 2015-10-08
US9290517B2 (en) 2016-03-22
RU2015109706A (ru) 2016-10-10
EP2888005A1 (en) 2015-07-01
BR112015003109A2 (pt) 2017-08-15
EP2888005A4 (en) 2016-04-20
AR092201A1 (https=) 2015-04-08
WO2014031515A1 (en) 2014-02-27
EP2888005B1 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
US9290517B2 (en) Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
CN103476258B (zh) 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
EP2887807B1 (en) Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators
US9382243B2 (en) Azabenzimidazole tetrahydropyran derivatives
US9868733B2 (en) Azabenzimidazole tetrahydrofuran derivatives
AU2012220595A1 (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2906040A1 (en) Novel benzimidazole tetrahydropyran derivatives
TWI449702B (zh) 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物
AU2015202898A1 (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150617

WD01 Invention patent application deemed withdrawn after publication